This leads to upregulation of ERR target genes encoding proteins for fatty acid oxidation, such as medium-chain acyl coenzyme A dehydrogenase
This triple action affects appetite, insulin response, and fat metabolism
Over the past decade, pharmaceutical GLP-1 agonists (initially developed for type 2 diabetes) have demonstrated dramatic weight loss benefits when given at higher doses
It functions by mimicking the incretin glucagon-like peptide-1, or GLP-1, hormone in the body, thereby enhancing insulin production and secretion to regulate blood sugar levels
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis
Our collaborative approach with insurers maximizes your benefits